Driving Laws and Prescribed Cannabis: ACT

A prescription doesn't change what the roadside test detects

Plenty of patients are genuinely surprised to learn that holding a valid prescription for medicinal cannabis offers no legal protection during a roadside drug test in the ACT. Not partial protection, and not a defence that applies if you can show you took it therapeutically. For prescribed cannabis containing THC, the prescription simply isn't part of the roadside equation.

It's one of those structural tensions in Australian law that doesn't get enough plain-language airtime, so let's go through exactly how it works in the Australian Capital Territory. The reason is simple enough: the test detects a compound, and the law is written around that compound, not around why a person has it.

The ACT road rules framework

Drug driving in the ACT is primarily governed by the Road Transport (Alcohol and Drugs) Act 1977 (ACT) and regulations made under it. The Act establishes two distinct offences that are relevant here.

The first is a presence offence: driving or being in charge of a vehicle while a prescribed illicit drug is present in your oral fluid, blood, or urine. The second is an impairment offence; driving whilst impaired by a drug, regardless of what the substance is.

The two offences work on different logic. A presence offence is about what can be detected in your body, so it doesn't ask how you were driving. An impairment offence is about how you were driving or behaving, so it doesn't depend on any particular substance appearing on a screen. Mixing the two up is one of the most common mistakes people make when they try to work out their own position.

Medicinal cannabis, depending on its composition, contains tetrahydrocannabinol (THC), which is a "prescribed illicit drug" for the purposes of roadside oral fluid testing across all Australian jurisdictions, including the ACT. The roadside saliva test does not ask whether your THC came from a Schedule 8 prescription or from an illegal source. It detects the compound. That's it.

If THC is present in your oral fluid at or above the detection threshold, you commit the presence offence. The fact that you were lawfully prescribed a Schedule 8 controlled drug is not a statutory defence under current ACT law. The label "prescribed illicit drug" can sound odd next to a lawful prescription, but it is a term about the substance named in the legislation, not a judgement about the patient.

What the oral fluid test actually screens for

ACT Police use roadside oral fluid testing devices that screen for THC (cannabis), methylamphetamine, and MDMA. The test looks for THC itself, the primary psychoactive cannabinoid; not for metabolites, not for cannabidiol (CBD), not for other minor cannabinoids.

A roadside screen is a first-stage check. Devices of this kind are designed to give a quick indication in the field, and the legal process around a positive result generally involves further steps. The detail of those steps sits in the Act and its regulations, which is another reason to read the primary text rather than rely on summaries.

This matters because many patients are prescribed products that contain both CBD and THC. Even if a product is lower in THC and higher in CBD, the THC component is still detectable in oral fluid for a period after use. How long? That varies considerably depending on frequency of use, the dose, individual pharmacokinetics, and the sensitivity of the device, but the short version is: the window is real and it isn't predictable down to the hour.

CBD-only products, on the other hand, do not contain THC and would not produce a positive result on a THC-specific oral fluid screen. But I'd flag here that "CBD-only" on a label isn't always the full story, product composition can vary, and patients should understand what their specific prescription contains. Check the product documentation and speak to your prescribing doctor about this directly. If you want background on how products are grouped, the explainer on medicinal cannabis product categories is a reasonable starting point, and the piece on HPLC testing of cannabinoids explains how composition is measured in the first place.

How prescribed cannabis reaches patients in the ACT

For context: most patients in the ACT access medicinal cannabis either through the TGA's Special Access Scheme (Category B, the most common pathway) or through an Authorised Prescriber who has TGA approval to prescribe to a class of patients. A smaller number access products listed on the Australian Register of Therapeutic Goods (ARTG). For a fuller picture of the access side, see our regulatory overview of medicinal cannabis access in the ACT.

The pathway a patient uses doesn't change the roadside outcome. Whether a product came through the Special Access Scheme, an Authorised Prescriber, or the ARTG, the oral fluid screen is looking for the same compound.

The ACT's own personal cannabis use laws (the Drugs of Dependence (Personal Cannabis Use) Act 2019 (ACT)) decriminalised possession of small amounts of cannabis for personal use by adults; but that's a separate legal space entirely, covering personal possession, not driving, and it doesn't interact with the road transport laws. The broader distinction between the two worlds is covered in medicinal vs recreational: the legal distinction.

Medicinal cannabis prescribed under the TGA framework remains a Schedule 4 (lower-THC formulations, including most CBD-dominant products) or Schedule 8 (THC-containing products) substance under the Poisons Standard (the instrument made under the Therapeutic Goods Act 1989 (Cth)). Patients in the ACT who hold Schedule 8 prescriptions must comply with ACT Health's controlled drug prescription requirements, these are administered under the Medicines, Poisons and Therapeutic Goods Act 2008 (ACT).

Scheduling is about how a medicine is supplied and controlled. Road safety law is a different instrument with a different purpose, which is why a substance can be perfectly lawful to hold under a prescription and still be detectable in a roadside test. If the history of how these categories developed interests you, a timeline of Australian drug scheduling sets it out.

The impairment offence and what it means in practice

Separate from the presence test, ACT Police can charge a driver with driving whilst impaired. This offence doesn't require a positive oral fluid screen, an officer can form the view that a driver is impaired based on behavioural observations, a field impairment assessment, or a blood test result.

This is where the interplay with prescriptions gets slightly more complicated, and honestly, more consequential for patients. A driver could theoretically test negative on a roadside oral fluid screen (if, say, enough time had passed since use) and still face an impairment charge if their driving or conduct raised concerns. Conversely, a positive presence result might be accompanied by an impairment assessment.

The practical lesson is that a negative screen is not the same as a clean bill of health. Impairment is judged on what is observed, and it can arise from many things beyond a single substance, including tiredness, other medicines, or the combined effect of several. That is part of why prescribers tend to raise driving as a general topic rather than only in relation to one product.

The ACT courts have not, as far as I've been able to track through published decisions, recognised a therapeutic-use defence to impairment charges in any consistent or statutory way. My view; and I'd hold this carefully, is that the absence of a clear legislative carve-out for prescribed patients represents a genuine policy gap that the ACT government has yet to address directly.

What patients and prescribers should know

The practical implications here genuinely affect people's lives, so it's worth stating them plainly rather than hiding behind a wall of disclaimers.

Here's what the law as currently written requires patients to reckon with:

• Driving after using any THC-containing medicinal cannabis product carries legal risk under the Road Transport (Alcohol and Drugs) Act 1977 (ACT), regardless of prescription status.
• There is no minimum threshold below which a positive oral fluid test becomes a defence, detection is the offence.
• CBD-only products (genuinely THC-free) are not picked up by current roadside oral fluid testing, but patients should verify the composition of their prescribed product with their doctor or pharmacist.
• Patients should discuss driving with their prescribing doctor before commencing any THC-containing treatment. This is a clinical and legal conversation worth having explicitly.
• ACT Health and Access Canberra publish guidance on controlled drug requirements; these are the authoritative territory-level sources, and they do change.

The TGA itself has published information noting that patients prescribed medicinal cannabis should be advised about the implications for driving. That's consistent with what prescribers in the ACT are expected to communicate. Driving is also only one setting where a prescribed medicine can collide with testing rules; the article on workplace drug testing and prescribed medicines covers a related one.

How this compares to other Australian jurisdictions

The ACT's position is broadly consistent with every other Australian jurisdiction. No state or territory currently provides a legislative exemption from roadside THC presence testing for medicinal cannabis patients. Western Australia, Victoria, New South Wales, Queensland, same framework. The presence offence is strict liability across the board, meaning the prosecution does not need to prove the driver intended to drive with the drug in their system.

Some jurisdictions have seen parliamentary inquiries or law reform commission discussions about whether a medicinal-use defence should be created, but as of the time of writing, no jurisdiction has enacted one. This is worth watching. The law here is genuinely in motion at the policy level even if it hasn't changed on the statute books yet.

For anyone wanting to understand more about why THC specifically triggers these rules, and why CBD does not; it helps to understand what THC actually does at the receptor level. The CB1 receptor, concentrated in the central nervous system, is the primary site of THC's psychoactive effects. That's the pharmacological basis for the legislature's specific interest in THC as a driving-relevant compound, as distinct from non-intoxicating cannabinoids.

Laws change, check current sources

Everything above reflects the legislative framework as I understand it at publication. Road transport law, medicinal cannabis access pathways, and the ACT's own drug legislation have all moved in the last five years and will almost certainly move again. If you're a patient, a prescriber, or anyone who needs to act on this information, go to the primary sources: ACT Legislation Register at legislation.act.gov.au, the TGA's medicinal cannabis pages at tga.gov.au, and Access Canberra for territory-level medicines regulation.

When you read a statute yourself, check that you are looking at the current version, and note the date the register says it was last updated. Secondary summaries, including this one, can lag behind amendments. For common reader questions on the wider topic, the cannabis and cannabinoids FAQ is a helpful companion.

Don't rely on a single article, including this one; as your final word on a question with legal consequences.

Sources used for this article:

• Information for patients, medicinal cannabis, TGA (tga.gov.au)
• Road Transport (Alcohol and Drugs) Act 1977 (ACT); ACT Legislation Register
• Medicinal cannabis, Australian Government Department of Health (health.gov.au)
• Cannabis drug facts, Alcohol and Drug Foundation (adf.org.au)

Marcus Hale, Regulatory researcher; TGA & access law